Evidence map›Paper›PMID 32581388›Full record

Observational studyScientific reports2020

Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population.

Darlen Cardoso de Carvalho, Alayde Vieira Wanderley, André Mauricio Ribeiro Dos Santos, Fabiano Cordeiro Moreira, Roberta Borges Andrade de Sá, Marianne Rodrigues Fernandes, Antonio André Conde Modesto, Tatiane Piedade de Souza, Amanda Cohen-Paes, Luciana Pereira Colares Leitão and 7 more

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Pharmacogenomic diversity in Amazonian Indigenous populations: implications for Berlin-Frankfurt-Münster acute lymphoblastic leukemia therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Association ofInternational journal of molecular sciences · 2024
    Article
  8. Article
  9. Article
  10. Variants ofGenes · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Pharmacogenomic Profile of Amazonian Amerindians.Journal of personalized medicine · 2022
    Article
  16. The Role ofGenes · 2022
    Article
  17. Characterization ofGenes · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Darlen Cardoso de CarvalhoOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Alayde Vieira WanderleyOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
André Mauricio Ribeiro Dos SantosHuman and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, PA, Brazil.
Fabiano Cordeiro MoreiraOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Roberta Borges Andrade de SáOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Marianne Rodrigues FernandesOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Antonio André Conde ModestoOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Tatiane Piedade de SouzaOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Amanda Cohen-PaesOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Luciana Pereira Colares LeitãoOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Juliana Carla Gomes RodriguesOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Artur Luiz da Costa da SilvaGenomics and Bioinformatics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, Brazil.
João Farias GuerreiroHuman and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, PA, Brazil.
Sidney SantosOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
André Salim KhayatOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Paulo Pimentel de AssumpçãoOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Ney Pereira Carneiro Dos SantosOncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil. npcsantos.ufpa@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children. Differences are found among ethnic groups in the results of the treatment of pediatric ALL. In general, children with a high level of native American ancestry tend to respond less positively to ALL treatments, which may be related to specific genomic variants found in native American groups. Despite the evidence, few data are available on the distribution of the pharmacogenomic variants relevant to the treatment of ALL in traditional Amerindian populations, such the those of the Amazon region. Given this, the present study investigated 27 molecular markers related to the treatment of ALL in Amerindians from Brazilian Amazonia and compared the frequencies with those recorded previously on five continents, that are available in the 1,000 Genomes database. The variation in the genotype frequencies among populations was evaluated using Fisher's exact test. The False Discovery Rate method was used to correct the results of the multiple analyses. Significant differences were found in the frequencies of the majority of markers between the Amerindian populations and those of other regions around the world. These findings highlight the unique genetic profile of the indigenous population of Brazilian Amazonia, which may reflect a distinct therapeutic profile for the treatment of ALL in these populations.

Indexed as

Pharmacogenomic VariantsAntineoplastic AgentsBrazilChildChild, PreschoolFemaleGenetic MarkersHumansIndians, South AmericanMalePrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsGenetic Markers

Identifiers

PMID32581388
PMCPMC7314857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.